Epigenome, Microbiome, and Metabolites: Unraveling the Complex Pathogenesis of Celiac Disease
Cell Biology International · 2026-11 · 50 (11)
DOI: 10.1002/cbin.70231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology International, online erschienen am 10.11.2026. Verfasst von Ali M Atoom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Celiac Disease, Epigenesis, Genetic, Epigenome, Gastrointestinal Microbiome. Die Arbeit nennt 76 Literaturangaben.
Abstract (Originalsprache)
Celiac disease (CeD) is a chronic autoimmune disease triggered by gluten consumption in genetically susceptible individuals, primarily those with HLA‐DQ2 or HLA‐DQ8 haplotypes. Although these genetic factors are responsible for a substantial portion of disease risk, they do not fully explain disease heritability or the rising incidence observed worldwide. Recent clinical studies highlight epigenetic modifications—including DNA methylation, histone modifications, non‐coding RNA regulation, and RNA methylation—as critical mediators bridging genetic susceptibility and environmental influences, such as gut microbiota dysbiosis, dietary patterns, early‐life exposures, infections, and pharmaceutical interventions. These epigenetic mechanisms modulate immune responses, intestinal barrier function, and inflammatory pathways, contributing to the loss of gluten tolerance and perpetuation of mucosal damage. Key players, including tissue transglutaminase 2 (TG2) and interferon‐gamma (IFN‐γ), form amplifying feedback loops that exacerbate pathogenesis. Bacterial metabolites and lifestyle factors further influence epigenetic landscapes, offering reversible targets for intervention. This review synthesizes current evidence on epigenetic alterations in CeD, emphasizing their interplay with microbiota and metabolites, tissue‐specific patterns, and potential as biomarkers. It also explores implications for novel therapeutic strategies beyond the gluten‐free diet, including epigenetic modulators and microbiota‐targeted approaches, to advance personalized prevention and management of CeD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al Ahliyya Amman University, Amman, Jordan.
- College of Pharmacy, Alnoor University, Mosul, Iraq.
- Department of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, India.
- University institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
- Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, India.
- Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
ORCID-Profile: Ali M Atoom, Omer Qutaiba B Allela
Zitieren
APA
Atoom, A. M., Allela, O. Q. B., Nayak, P. P., Arora, V., Singla, S., Athab, Z. H., Urazbaeva, D., & Usmanov, R. (2026). Epigenome, Microbiome, and Metabolites: Unraveling the Complex Pathogenesis of Celiac Disease. Cell Biology International, 50(11). https://doi.org/10.1002/cbin.70231
Vancouver
Atoom AM, Allela OQB, Nayak PP, Arora V, Singla S, Athab ZH, et al. Epigenome, Microbiome, and Metabolites: Unraveling the Complex Pathogenesis of Celiac Disease. Cell Biology International. 2026;50(11). doi:10.1002/cbin.70231
BibTeX
@article{Atoom2026,
author = {Atoom, Ali M and Allela, Omer Qutaiba B and Nayak, Priya Priyadarshini and Arora, Vimal and Singla, Siya and Athab, Zainab H and Urazbaeva, Dilbar and Usmanov, Rasul},
title = {Epigenome, Microbiome, and Metabolites: Unraveling the Complex Pathogenesis of Celiac Disease},
journal = {Cell Biology International},
year = {2026},
volume = {50},
number = {11},
doi = {10.1002/cbin.70231}
}
EUVIMED